Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis

Samuel M Lindner; Christopher B Fordyce; Anne S Hellkamp; Yuliya Lokhnygina; Jonathan P Piccini; Günter Breithardt; Kenneth W Mahaffey; Daniel E Singer; Werner Hacke; Jonathan L Halperin; Graeme J Hankey; Scott D Berkowitz; Christopher C Nessel; Richard C Becker; Keith A A Fox; Manesh R Patel; ROCKET AF Steering Committee and Investigators

doi:10.1161/CIRCULATIONAHA.116.024666

Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis

Circulation. 2017 Mar 7;135(10):1001-1003. doi: 10.1161/CIRCULATIONAHA.116.024666.

Authors

Samuel M Lindner¹, Christopher B Fordyce¹, Anne S Hellkamp¹, Yuliya Lokhnygina¹, Jonathan P Piccini¹, Günter Breithardt¹, Kenneth W Mahaffey¹, Daniel E Singer¹, Werner Hacke¹, Jonathan L Halperin¹, Graeme J Hankey¹, Scott D Berkowitz¹, Christopher C Nessel¹, Richard C Becker¹, Keith A A Fox¹, Manesh R Patel²; ROCKET AF Steering Committee and Investigators

Affiliations

¹ From Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (S.M.L., C.B.F., A.S.H., Y.L., J.P.P., M.R.P.); Division of Cardiology, University of British Columbia, Vancouver, Canada (C.B.F.); Department of Cardiovascular Medicine, University of Münster, Germany (G.B.); Stanford University School of Medicine, CA (K.W.M.); Massachusetts General Hospital and Harvard Medical School, Boston (D.E.S.); Ruprecht-Karls-University, Heidelberg, Germany (W.H.); Cardiovascular Institute, Mount Sinai Medical Center, NY (J.L.H.); School of Medicine and Pharmacology, The University of Western Australia, Crawley (G.J.H.); Bayer HealthCare Pharmaceuticals, Parsippany, NJ (S.D.B.); Janssen Research and Development LLC, Raritan, NJ (C.C.N.); University of Cincinnati College of Medicine, OH (R.C.B.); and University of Edinburgh and Royal Infirmary of Edinburgh, UK (K.A.A.F.).
² From Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (S.M.L., C.B.F., A.S.H., Y.L., J.P.P., M.R.P.); Division of Cardiology, University of British Columbia, Vancouver, Canada (C.B.F.); Department of Cardiovascular Medicine, University of Münster, Germany (G.B.); Stanford University School of Medicine, CA (K.W.M.); Massachusetts General Hospital and Harvard Medical School, Boston (D.E.S.); Ruprecht-Karls-University, Heidelberg, Germany (W.H.); Cardiovascular Institute, Mount Sinai Medical Center, NY (J.L.H.); School of Medicine and Pharmacology, The University of Western Australia, Crawley (G.J.H.); Bayer HealthCare Pharmaceuticals, Parsippany, NJ (S.D.B.); Janssen Research and Development LLC, Raritan, NJ (C.C.N.); University of Cincinnati College of Medicine, OH (R.C.B.); and University of Edinburgh and Royal Infirmary of Edinburgh, UK (K.A.A.F.). manesh.patel@duke.edu.

PMID: 28264892
DOI: 10.1161/CIRCULATIONAHA.116.024666

No abstract available

Keywords: atrial fibrillation; renal function.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Anticoagulants / adverse effects*
Anticoagulants / therapeutic use
Atrial Fibrillation / complications
Creatinine / urine
Embolism / prevention & control
Factor Xa Inhibitors / adverse effects*
Factor Xa Inhibitors / therapeutic use
Humans
Kidney / drug effects*
Kidney / metabolism
Kidney / physiopathology
Kidney Function Tests
Rivaroxaban / adverse effects*
Rivaroxaban / therapeutic use
Stroke / prevention & control
Vitamin K / antagonists & inhibitors
Warfarin / adverse effects*
Warfarin / therapeutic use

Substances

Anticoagulants
Factor Xa Inhibitors
Vitamin K
Warfarin
Rivaroxaban
Creatinine

Associated data

ClinicalTrials.gov/NCT00403767